![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2023/06/01/2680276/0/en/Angion-Biomedia-Corp-Announces-1-for-10-Reverse-Stock-Split.html
https://www.globenewswire.com/news-release/2023/01/17/2589654/0/en/Elicio-Therapeutics-and-Angion-Enter-into-Definitive-Merger-Agreement.html
https://www.globenewswire.com//news-release/2022/12/22/2578302/0/en/Angion-Receives-Nasdaq-Notice-Regarding-Minimum-Bid-Price-Requirements.html
https://www.globenewswire.com/news-release/2022/08/15/2498535/0/en/Angion-Provides-Corporate-Update-and-Reports-Second-Quarter-2022-Financial-Results.html
https://www.fiercebiotech.com/biotech/angion-hangs-sale-sign-stops-drug-development-work-after-flops-force-search-exit
https://www.globenewswire.com/news-release/2022/07/25/2485413/0/en/Angion-Announces-Process-to-Explore-Strategic-Alternatives-for-Enhancing-and-Preserving-Shareholder-Value.html
https://www.fiercebiotech.com/biotech/all-strategic-and-operational-options-angion-and-its-pipeline-going-forward
https://www.globenewswire.com/news-release/2022/06/29/2471655/0/en/Angion-Announces-Discontinuation-of-Phase-2-Trial-of-ANG-3070-in-Patients-with-Primary-Proteinuric-Kidney-Disease.html